Abstract
BACKGROUND—Inhaled corticosteroids are known to be beneficial for patients with asthma, but their role in treating patients with stable chronic obstructive pulmonary disease (COPD) remains controversial. A study was undertaken to determine whether inhaled corticosteroids are of functional benefit in patients who did not show improvement with a trial of oral corticosteroids. METHODS—In phase I patients with stable COPD were given a two week course of oral placebo followed by two weeks of prednisone 40 mg per day in a single blind manner to distinguish between responders and non-responders to oral corticosteroids. In phase II a double blind, randomised, parallel group trial of inhaled budesonide 1600 µg per day versus placebo was carried out in 79 non-responders to oral corticosteroids. The primary outcome measure was forced expiratory volume in one second (FEV1), and secondary outcome measures were exercise capacity, dyspnoea with exertion, quality of life, peak expiration flow rate, and respiratory symptoms. RESULTS—Randomisation allocated 39 subjects to inhaled corticosteroids and 40 to placebo. There was no difference in the change in FEV1 from baseline between the treatment and placebo groups; mean difference -12 ml (95% CI -88 to 63) at three months and -4 ml (95% CI -95 to 87) at six months. The proportion of patients with a 15% or greater improvement was no higher among those receiving inhaled corticosteroids than in the placebo group at any of the follow up visits. Changes in secondary outcomes were also no different. CONCLUSIONS—Inhaledcorticosteroids, even at high doses, were of no physiological or functional benefit in these patients with advanced COPD.
Full Text
The Full Text of this article is available as a PDF (125.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Auffarth B., Postma D. S., de Monchy J. G., van der Mark T. W., Boorsma M., Koëter G. H. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax. 1991 May;46(5):372–377. doi: 10.1136/thx.46.5.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Butland R. J., Pang J., Gross E. R., Woodcock A. A., Geddes D. M. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) 1982 May 29;284(6329):1607–1608. doi: 10.1136/bmj.284.6329.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Callahan C. M., Dittus R. S., Katz B. P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 1991 Feb 1;114(3):216–223. doi: 10.7326/0003-4819-114-3-216. [DOI] [PubMed] [Google Scholar]
- Guyatt G. H., Berman L. B., Townsend M., Pugsley S. O., Chambers L. W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. doi: 10.1136/thx.42.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guyatt G. H., Pugsley S. O., Sullivan M. J., Thompson P. J., Berman L., Jones N. L., Fallen E. L., Taylor D. W. Effect of encouragement on walking test performance. Thorax. 1984 Nov;39(11):818–822. doi: 10.1136/thx.39.11.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hall T. G., Kasik J. E., Bedell G. N., Schaiff R. A. The efficacy of inhaled beclomethasone in chronic obstructive airway disease. Pharmacotherapy. 1989;9(4):232–239. doi: 10.1002/j.1875-9114.1989.tb04131.x. [DOI] [PubMed] [Google Scholar]
- Jaeschke R., Singer J., Guyatt G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 Dec;10(4):407–415. doi: 10.1016/0197-2456(89)90005-6. [DOI] [PubMed] [Google Scholar]
- Kerstjens H. A., Brand P. L., Hughes M. D., Robinson N. J., Postma D. S., Sluiter H. J., Bleecker E. R., Dekhuijzen P. N., de Jong P. M., Mengelers H. J. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992 Nov 12;327(20):1413–1419. doi: 10.1056/NEJM199211123272003. [DOI] [PubMed] [Google Scholar]
- Knudson R. J., Lebowitz M. D., Holberg C. J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983 Jun;127(6):725–734. doi: 10.1164/arrd.1983.127.6.725. [DOI] [PubMed] [Google Scholar]
- Lacasse Y., Guyatt G. H., Goldstein R. S. The components of a respiratory rehabilitation program: a systematic overview. Chest. 1997 Apr;111(4):1077–1088. doi: 10.1378/chest.111.4.1077. [DOI] [PubMed] [Google Scholar]
- Osterman J. W., Armstrong B. G., Ledoux E., Sloan M., Ernst P. Comparison of French and English versions of the American Thoracic Society respiratory questionnaire in a bilingual working population. Int J Epidemiol. 1991 Mar;20(1):138–143. doi: 10.1093/ije/20.1.138. [DOI] [PubMed] [Google Scholar]
- Overbeek S. E., Hilvering C., Bogaard J. M., Birkenhäger J. C., Neijens H. J. A comparison of the efficacy of high dose and normal dose budesonide in prednisone dependent patients with chronic obstructive lung disease (COLD). Eur J Respir Dis Suppl. 1986;146:581–584. [PubMed] [Google Scholar]
- Shim C. S., Williams M. H., Jr Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease. Am J Med. 1985 Apr;78(4):655–658. doi: 10.1016/0002-9343(85)90409-7. [DOI] [PubMed] [Google Scholar]
- Thompson A. B., Mueller M. B., Heires A. J., Bohling T. L., Daughton D., Yancey S. W., Sykes R. S., Rennard S. I. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis. 1992 Aug;146(2):389–395. doi: 10.1164/ajrccm/146.2.389. [DOI] [PubMed] [Google Scholar]
- Wardman A. G., Simpson F. G., Knox A. J., Page R. L., Cooke N. J. The use of high dose inhaled beclomethasone dipropionate as a means of assessing steroid responsiveness in obstructive airways disease. Br J Dis Chest. 1988 Apr;82(2):168–171. doi: 10.1016/0007-0971(88)90038-1. [DOI] [PubMed] [Google Scholar]
- Weir D. C., Burge P. S. Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax. 1993 Apr;48(4):309–316. doi: 10.1136/thx.48.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]